Exophthalmos clinical trials at UCLA
1 research study open to eligible people
open to eligible people ages 18 years and up
The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).
Los Angeles, California and other locations